Category Archives: 2025

PeproMene Bio’s PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting

Posted on November 20, 2025 by steve@pepromenebio.com

To find the article on the web: Click here   IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ — PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 … Continue reading →

Posted in 2025 | Leave a comment

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

Posted on May 20, 2025 by steve@pepromenebio.com

To find the article on the web: Click here   IRVINE, Calif., May 20, 2025 /PRNewswire/ — PeproMene Bio, Inc. (PMB) a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first r/r FL patient treated in … Continue reading →

Posted in 2025 | Leave a comment